European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478- [ Recommended · 2026 ]
A central purpose of Ph. Eur. 0478 is defining the physical tests that finished batches must satisfy. The monograph cross-references vital technical chapters to govern structural durability and mass reproducibility: The Ph.Eur. approach to tablet splitting
The section of Monograph 0478 sets baseline requirements for current Good Manufacturing Practices (cGMP). Microbiological Quality
: Formulated with carbonates to react in water and release carbon dioxide for rapid dispersion.
Understanding how to apply the monograph in practice is crucial for manufacturers. European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-
user wants a long article about "European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-". I need to provide comprehensive information. I'll break down the search into key aspects: general information about Ph. Eur., the specific Tablets monograph 0478, its content, historical context, and related regulatory guidelines. I'll search in English. search results show several relevant pages. I need to open them to gather detailed information. I'll open the drugfuture.com page (result 0) for the full text of the monograph. I'll also open the GMP Compliance Advisor page (result 2) for the revision history. The EDQM FAQ page (result 1) might provide additional context. The Pink Citeline page (result 5) and the USP page (result 6) might also be useful. I'll open these pages. pages provide a lot of information. The drugfuture.com page gives the full monograph text. The GMP Compliance Advisor page details the 2018 revision. The EDQM FAQ explains disintegration testing. The Pink Citeline PDF discusses dissolution testing policies. The USP PDF provides historical revision data. The AGES study mentions divisibility testing. The WhatDoTheyKnow page discusses break-mark requirements. I need to structure the article. I'll cover the monographs definition and scope, the various categories of tablets, production quality parameters, the evolution of the monograph, its role in regulatory compliance, and future developments. I'll cite the sources appropriately. European Pharmacopoeia (Ph. Eur.) is a foundational text for the quality control of medicines across Europe and beyond. Among its most referenced sections is the general monograph . This monograph defines the legally binding quality standards for one of the most common pharmaceutical dosage forms: the tablet.
By understanding and adhering to the standards of Monograph 0478, manufacturers can produce safe, effective, and reliable products that meet the high expectations of regulators and, most importantly, the needs of patients worldwide.
: Allowed up to 60 minutes (excluding film-coated, which are 30 minutes). Soluble/Dispersible : Must break down within 3 minutes . 2. Dissolution (General Chapter 2.9.3) A central purpose of Ph
: Measured in Newtons, typically on a sample of 10 tablets to determine the force required for disruption.
: Uncoated tablets containing acid substances and carbonates/hydrogen carbonates. They react rapidly in water to release carbon dioxide, dissolving or dispersing the drug for consumption.
Following Ph. Eur. standards is legally binding for marketing medicines in signatory states. It provides the scientific basis for quality control throughout a product's life cycle—from development to final distribution. Understanding how to apply the monograph in practice
Pharmaceutical manufacturing operates on a global scale, making regulatory alignment highly desirable. The EDQM actively participates in the alongside the United States Pharmacopeia (USP) and the Japanese Pharmacopoeia (JP).
This article provides an in-depth analysis of Ph. Eur. Monograph 0478, exploring its scope, core quality requirements, critical testing methodologies, and its profound impact on pharmaceutical manufacturing and regulatory compliance. 1. Scope and Definition of Monograph 0478
: Modern forms that disintegrate rapidly in the mouth without water, typically within 3 minutes .